title: Epirubicin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.
abstract: Epirubicin (EPI) has strong cytotoxic activity that makes it a potential candidate for the treatment of malignant gliomas. To minimize toxicity and increase CNS penetration, EPI was incorporated into biodegradable polymers, and its in vitro and in vivo properties were studied. 9L, F98, C6, U251, and EMT-6 cell lines were treated with EPI in vitro and cell viability was measured. Toxicity of EPI/polycarboxyphenoxypropane-sebacic-acid (pCPP:SA) polymers was tested in vivo using F344 rats intracranially implanted with EPI polymers (2-50% by weight). The efficacy of 50% EPI:pCPP:SA polymers was determined in F344 rats intracranially challenged with 9L and treated either simultaneously or 5 days after tumor implantation. The efficacy of 50% EPI:pCCP:SA polymers administered on Day 5 in combination with oral TMZ was determined in rats intracranially challenged with 9L gliosarcoma. EPI was cytotoxic in all cell lines used in vitro. Intracranial implantation of the EPI polymers in rats generated neither local nor systemic toxicity. Animals receiving intracranial EPI on Day 5 had 50% long-term survivors (LTS), which was superior to local EPI delivered on Day 0 (LTS = 12.5%). Animals receiving intracranial EPI in combination with oral TMZ had 75% LTS whereas no other group had LTS. In those EPI treated animals that died before the controls there was evidence of intracranial hemorrhage. Systemic epirubicin resulted in high toxicity levels and early deaths in all the experiments. EPI polymers, alone or in combination with oral TMZ, is an effective therapeutic modality against experimental 9L gliosarcoma.
authors.affiliation: Hunterian Neurosurgical Research Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
authors.forename: Violette Renard
authors.initials: VR
authors.lastname: Recinos
authors.forename: Kimon
authors.initials: K
authors.lastname: Bekelis
authors.forename: Shira G
authors.initials: SG
authors.lastname: Ziegler
authors.forename: Ditty
authors.initials: D
authors.lastname: Vick
authors.forename: Samuel
authors.initials: S
authors.lastname: Hertig
authors.forename: Betty M
authors.initials: BM
authors.lastname: Tyler
authors.forename: Khan W
authors.initials: KW
authors.lastname: Li
authors.forename: Thomas
authors.initials: T
authors.lastname: Kosztowski
authors.forename: Federico G
authors.initials: FG
authors.lastname: Legnani
authors.forename: Henry
authors.initials: H
authors.lastname: Brem
authors.forename: Alessandro
authors.initials: A
authors.lastname: Olivi
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D016503:Drug Delivery Systems / Q000379:methods; D015251:Epirubicin / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D011108:Polymers / Q000008:administration & dosage* / Q000494:pharmacology; D051381:Rats; D011916:Rats, Inbred F344; D013778:Tetrazolium Salts; D013844:Thiazoles; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D011108:Polymers; D013778:Tetrazolium Salts; D013844:Thiazoles; D015251:Epirubicin; C022616:thiazolyl blue
references.citation: Biochemistry. 1987 Jun 30;26(13):3776-81
references.pmid: 2820475
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2903-9
references.pmid: 16782930
references.citation: Ann Oncol. 2004 Oct;15(10):1517-26
references.pmid: 15367413
references.citation: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references.pmid: 6606682
references.citation: Neuro Oncol. 2003 Apr;5(2):79-88
references.pmid: 12672279
references.citation: Science. 1982 Jul 16;217(4556):248-50
references.pmid: 7089561
references.citation: J Neurooncol. 1995 Nov;26(2):111-23
references.pmid: 8787853
references.citation: J Neurosurg. 2009 Mar;110(3):583-8
references.pmid: 19046047
references.citation: Ann Surg Oncol. 2008 Oct;15(10):2887-93
references.pmid: 18636295
references.citation: Lancet. 1995 Apr 22;345(8956):1008-12
references.pmid: 7723496
references.citation: Gan To Kagaku Ryoho. 2006 Mar;33(3):318-23
references.pmid: 16531711
references.citation: Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9
references.pmid: 9218294
references.citation: Anticancer Res. 2006 Jan-Feb;26(1B):581-4
references.pmid: 16739324
references.citation: J Natl Compr Canc Netw. 2005 Sep;3(5):721-8
references.pmid: 16194460
references.citation: Pharmacol Ther. 1987;32(2):89-106
references.pmid: 3037573
references.citation: Biochem Pharmacol. 1989 Jan 1;38(1):167-72
references.pmid: 2910297
references.citation: Expert Rev Neurother. 2003 Jul;3(4):533-46
references.pmid: 19810937
references.citation: Anticancer Drugs. 2007 Jul;18(6):621-32
references.pmid: 17762390
references.citation: Curr Pharm Des. 2004;10(12):1341-53
references.pmid: 15134485
references.citation: Neuro Oncol. 2001 Oct;3(4):246-50
references.pmid: 11584894
references.citation: Semin Oncol. 2006 Jun;33(3 Suppl 8):S15-21
references.pmid: 16781285
references.citation: Brain. 1989 Apr;112 ( Pt 2):457-69
references.pmid: 2706439
references.citation: Anticancer Res. 2005 Nov-Dec;25(6B):3825-31
references.pmid: 16312042
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1375-82
references.pmid: 11870182
references.citation: Cancer Res. 2005 Dec 15;65(24):11631-8
references.pmid: 16357174
references.citation: Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275
references.pmid: 16482400
references.citation: Biochem Pharmacol. 1989 Nov 15;38(22):4069-74
references.pmid: 2597184
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Cancer J. 2003 May-Jun;9(3):149-56
references.pmid: 12952300
references.citation: JAMA. 2005 Feb 2;293(5):557-64
references.pmid: 15687310